Lowe et al, “5,7-Diphenyl-3-ureidohexahydrozepin-2-ones as Cholecystokinin-B Receptor Ligands”, Bioorganic & Medicinal Chem. Letter, vol. 4, No. 24, pp. 2877-2882, 1994. |
Semple et al, “Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamide Moieties”, J. Med. Chem. 1996, 39, 4531-4536. |
Angelucci et al, “Synthesis and Amnesia-Reversal Activity of a Series of 7-and 5-Membered 3-Acylamino Lactams”, Journal of Medicinal Chemistry, vol. 36, No. 11, May 28, 1993. |
Sreenivasan et al, “Synthesis and Dopamine Receptor Modulating Activity of Lactam Conformationally Constrained Analogues of Pro-Leu-Gly-NH2”, J. Med. Chem. 1993, 36, 256-263. |
Skiles et al, “Elastase Inhibitors Containing Conformationally Restricted Lactams as P3-P2 Dipeptide Replacements”, Bioorganic & medicinal Chem. Letters, vol. 3, No. 4, pp. 773-778, 1993. |
Adang et al, “Novel Acylguanidine Containing Thrombin Inhibitors With Reduced Basicity at the P1 Moiety”, Bioorganic & Medicinal Chem. Letters 8 (1998), 3603-3608. |
Freidinger et al, “Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides”, J. Org. Chem. 1982, 47, 104-109. |